Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA1 | P56199 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 4/20 | 0.43 |
| ▸ | EDNRA | P25101 | 2/20 | 0.43 |
| ▸ | ACLY | P53396 | 3/20 | 0.42 |
| ▸ | CPT1A | P50416 | 1/20 | 0.41 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.41 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.41 |
| ▸ | EDNRB | P24530 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22981683 | 1.00 | ITGA1 (0.48) | ITGA1MEN1LMNAMAPTALOX12 | |
| SCHEMBL23010370 | 0.90 | MCL1 (0.49) | MEN1MAPTKMT2AEDNRAACLY | |
| SCHEMBL29434875 | 0.90 | MCL1 (0.49) | MEN1MAPTKMT2AEDNRAACLY | |
| SCHEMBL29434842 | 0.88 | SLC22A12 (0.44) | MEN1LMNAKMT2AEDNRAACLY | |
| SCHEMBL22981705 | 0.88 | SLC22A12 (0.44) | MEN1LMNAKMT2AEDNRAACLY | |
| SCHEMBL22980372 | 0.82 | ACLY (0.54) | ACLY | |
| SCHEMBL22980371 | 0.82 | ACLY (0.54) | CCR2ACLYSLC40A1 | |
| SCHEMBL29434884 | 0.82 | ACLY (0.54) | ACLY | |
| SCHEMBL23010358 | 0.81 | L3MBTL1 (0.43) | MEN1LMNAMAPTKMT2AACLY | |
| SCHEMBL22980994 | 0.81 | HSD11B1 (0.47) | CCR2EDNRAACLYSLC40A1EDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114174266-A | Arylsulfonamide derivatives as MGLUR4 negative allosteric modulators | 豪夫迈·罗氏有限公司 | 2022-03-11 | — | — | CN | claimed |
| US-12065399-B2 | Arylsulfonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-08-20 | — | — | US | disclosed |
| EP-4013495-B1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2023-09-27 | — | — | EP | disclosed |
| US-20220169599-A1 | ARYLSULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-06-02 | — | — | US | disclosed |
| CN-114174266-A | Arylsulfonamide derivatives as MGLUR4 negative allosteric modulators | 豪夫迈·罗氏有限公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169599-A1 | ARYLSULFONAMIDE DERIVATIVES | ARSA, SULT1E1, STS | ITGA1 3596/4885MEN1 2505/4885LMNA 1334/4885 |
| US-12065399-B2 | Arylsulfonamide derivatives | ARSA, SULT1E1, STS | ITGA1 3596/4885MEN1 2505/4885LMNA 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.